Company’s Thin Film Freezing platform to be developed for use in rapidly neutralizing chemical and biological threats at vulnerable tissue barriers to increase soldier protection and decrease operational burden AUSTIN, Texas --(BUSINESS WIRE)--Apr. 13, 2021-- TFF Pharmaceuticals, Inc.

AUSTIN, Texas --(BUSINESS WIRE)--Mar. 26, 2021-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (“TFF”) technology platform, today announced that it has

Reports positive Phase 1 study results for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder Awarded subcontract license by U.S. government agency to formulate biologic countermeasures to be used by the U.S. military Announces feasibility agreements with Greenlight Biosciences for